EA200200921A1 - Полуамиды малоновой кислоты и их производные в качестве лигандов тиреоидных рецепторов - Google Patents

Полуамиды малоновой кислоты и их производные в качестве лигандов тиреоидных рецепторов

Info

Publication number
EA200200921A1
EA200200921A1 EA200200921A EA200200921A EA200200921A1 EA 200200921 A1 EA200200921 A1 EA 200200921A1 EA 200200921 A EA200200921 A EA 200200921A EA 200200921 A EA200200921 A EA 200200921A EA 200200921 A1 EA200200921 A1 EA 200200921A1
Authority
EA
Eurasian Patent Office
Prior art keywords
diseases
derivatives
malonic acid
thyroid
ligands
Prior art date
Application number
EA200200921A
Other languages
English (en)
Inventor
Гэри Эрик Аспнес
Юан-Чинг Фоебе Чианг
Кимберли Гейл Эстеп
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA200200921A1 publication Critical patent/EA200200921A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/80—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к новым лигандам тиреоидных рецепторов и, более конкретно, полуамидам малоновой кислоты и их производным формулы I, которые могут использоваться при лечении ожирения, избыточной массы тела, гиперлипидемии, глаукомы, сердечной аритмии, кожных заболеваний, болезней щитовидной железы, гипотиреоза, рака щитовидной железы и родственных нарушений и заболеваний, таких как сахарный диабет, атеросклероз, гипертензия, коронарное заболевание сердца, застойная сердечная недостаточность, гиперхолестеринемия, депрессия и остеопороз. Настоящее изобретение относится также к способам, фармацевтическим композициям и наборам для лечения таких заболеваний и нарушений.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200200921A 2000-03-31 2001-03-07 Полуамиды малоновой кислоты и их производные в качестве лигандов тиреоидных рецепторов EA200200921A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19361800P 2000-03-31 2000-03-31
PCT/IB2001/000317 WO2001072692A1 (en) 2000-03-31 2001-03-07 Malonamic acids and derivatives thereof as thyroid receptor ligands

Publications (1)

Publication Number Publication Date
EA200200921A1 true EA200200921A1 (ru) 2003-02-27

Family

ID=22714346

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200200921A EA200200921A1 (ru) 2000-03-31 2001-03-07 Полуамиды малоновой кислоты и их производные в качестве лигандов тиреоидных рецепторов

Country Status (38)

Country Link
US (1) US20070173548A1 (ru)
EP (1) EP1268404B1 (ru)
JP (1) JP3866977B2 (ru)
KR (1) KR20020089420A (ru)
CN (1) CN1422246A (ru)
AP (1) AP2002002634A0 (ru)
AR (1) AR033516A1 (ru)
AT (1) ATE382602T1 (ru)
AU (1) AU2001237665A1 (ru)
BG (1) BG107036A (ru)
BR (1) BR0109625A (ru)
CA (1) CA2403902C (ru)
CR (1) CR6742A (ru)
CZ (1) CZ20023190A3 (ru)
DE (1) DE60132181D1 (ru)
DZ (1) DZ3276A1 (ru)
EA (1) EA200200921A1 (ru)
EE (1) EE200200566A (ru)
GT (1) GT200100041A (ru)
HK (1) HK1052498A1 (ru)
HU (1) HUP0300329A3 (ru)
IL (1) IL151376A0 (ru)
IS (1) IS6516A (ru)
MA (1) MA26886A1 (ru)
MX (1) MXPA02009702A (ru)
NO (1) NO20024639L (ru)
NZ (1) NZ520660A (ru)
OA (1) OA12237A (ru)
PA (1) PA8513801A1 (ru)
PE (1) PE20011186A1 (ru)
PL (1) PL358596A1 (ru)
SK (1) SK13762002A3 (ru)
SV (1) SV2002000357A (ru)
TN (1) TNSN01048A1 (ru)
TR (1) TR200202249T2 (ru)
WO (1) WO2001072692A1 (ru)
YU (1) YU74102A (ru)
ZA (1) ZA200207444B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599942B1 (en) 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
US6790978B2 (en) 1999-03-29 2004-09-14 Novartis Ag Thyromimetic organic compounds
HUP0301777A3 (en) * 2000-02-17 2010-09-28 Bristol Myers Squibb Co Aniline-derived ligands for the thyroid receptor, pharmaceutical compositions comprising thereof and their use
JP2004517851A (ja) * 2000-12-27 2004-06-17 バイエル アクチェンゲゼルシャフト 甲状腺受容体のリガンドとしてのインドール誘導体
GB2374009A (en) * 2001-02-12 2002-10-09 Novartis Ag Method of treating hair loss
AU2002331145B2 (en) 2001-08-24 2008-07-10 Karo Bio Ab Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
EP1689383B1 (en) 2003-11-19 2012-10-31 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
CA2606499C (en) 2005-05-26 2017-06-13 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
GB0606201D0 (en) * 2006-03-28 2006-05-10 Karobio Ab Improved crytalline material
WO2008017381A1 (de) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
US8633245B2 (en) * 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
EP2272817A4 (en) * 2008-04-11 2011-12-14 Inst Med Molecular Design Inc INHIBITOR OF PAI-1
AR072707A1 (es) 2008-07-09 2010-09-15 Sanofi Aventis Compuestos heterociclicos, procesos para su preparacion, medicamentos que comprenden estos compuestos y el uso de los mismos
KR20110077018A (ko) 2008-10-27 2011-07-06 카딜라 핼쓰캐어 리미티드 갑상선 수용체 리간드
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010086878A2 (en) 2009-01-09 2010-08-05 Cadila Healthcare Limited Thyroid receptor modulators
CA2771278A1 (en) 2009-08-26 2011-03-03 Sanofi Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809324B2 (en) 2011-03-08 2014-08-19 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120051A1 (de) 2011-03-08 2012-09-13 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8846666B2 (en) 2011-03-08 2014-09-30 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
DK2695611T3 (en) 2012-08-06 2015-01-05 Wolff August Gmbh & Co Kg Arzneimittel Dr Eprotirome for use in the prevention and / or treatment of hair disorders and their compositions
EP3610890A1 (en) 2012-11-14 2020-02-19 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2015156302A1 (ja) * 2014-04-09 2015-10-15 ゴールドクレスト医薬研究所株式会社 皮膚症状の改善剤、育毛剤又はスリミング剤
CN110198719A (zh) 2016-11-21 2019-09-03 维京治疗公司 治疗糖原贮积病的方法
EA201992703A1 (ru) 2017-06-05 2020-04-15 Вайкинг Терапьютикс, Инк. Композиции для лечения фиброза
CN107474007B (zh) * 2017-08-28 2019-04-19 上海再启生物技术有限公司 一种制备3，6-二羟基苯二甲酰亚胺的方法
AU2019238090A1 (en) 2018-03-22 2020-10-08 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound
CN112300133A (zh) * 2019-07-31 2021-02-02 深圳微芯生物科技股份有限公司 一种杂环化合物及其应用
EP3878837A1 (en) * 2020-03-11 2021-09-15 OM Pharma SA 2,5- or 2,6-disubstituted hydroquinone derivatives with at least one carboxy, sulfo or amido group useful as medicaments

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069343A (en) * 1973-03-23 1978-01-17 American Home Products Corporation Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions
US4554290A (en) * 1983-06-17 1985-11-19 Ciba-Geigy Corporation Oxamic acid derivatives
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
US5061798A (en) * 1985-01-18 1991-10-29 Smith Kline & French Laboratories, Ltd. Benzyl pyridyl and pyridazinyl compounds
US5232947A (en) * 1988-07-04 1993-08-03 Meiji Seika Kaisha, Ltd. Oxamic acid compounds and pharmaceutical composition for use in improvement of damaged cerebral functions of brain
US5284971A (en) * 1992-07-16 1994-02-08 Syntex (U.S.A.) Inc. 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents
DK0580550T3 (da) * 1992-07-21 1998-02-02 Ciba Geigy Ag Oxamidsyrederivater som hypercholesterolæmiske midler
CO5160290A1 (es) * 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
CA2374263A1 (en) * 1999-06-01 2000-12-07 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylether derivatives
US6664291B2 (en) * 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands

Also Published As

Publication number Publication date
YU74102A (sh) 2006-03-03
WO2001072692A1 (en) 2001-10-04
TNSN01048A1 (fr) 2005-11-10
DZ3276A1 (fr) 2001-10-04
PA8513801A1 (es) 2002-02-21
EE200200566A (et) 2004-06-15
BR0109625A (pt) 2003-04-22
HK1052498A1 (zh) 2003-09-19
CR6742A (es) 2003-11-25
IS6516A (is) 2002-08-21
TR200202249T2 (tr) 2003-01-21
MXPA02009702A (es) 2003-03-27
CZ20023190A3 (cs) 2003-10-15
HUP0300329A2 (hu) 2003-07-28
CA2403902C (en) 2007-04-24
JP3866977B2 (ja) 2007-01-10
JP2003528847A (ja) 2003-09-30
NZ520660A (en) 2004-03-26
IL151376A0 (en) 2003-04-10
NO20024639D0 (no) 2002-09-27
EP1268404B1 (en) 2008-01-02
AP2002002634A0 (en) 2002-09-30
GT200100041A (es) 2002-03-22
KR20020089420A (ko) 2002-11-29
EP1268404A1 (en) 2003-01-02
SV2002000357A (es) 2002-07-16
ZA200207444B (en) 2003-09-17
HUP0300329A3 (en) 2004-08-30
AR033516A1 (es) 2003-12-26
CN1422246A (zh) 2003-06-04
PL358596A1 (en) 2004-08-09
NO20024639L (no) 2002-09-27
US20070173548A1 (en) 2007-07-26
ATE382602T1 (de) 2008-01-15
MA26886A1 (fr) 2004-12-20
DE60132181D1 (de) 2008-02-14
PE20011186A1 (es) 2001-11-15
BG107036A (bg) 2003-04-30
AU2001237665A1 (en) 2001-10-08
SK13762002A3 (sk) 2004-01-08
OA12237A (en) 2003-10-23
CA2403902A1 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
EA200200921A1 (ru) Полуамиды малоновой кислоты и их производные в качестве лигандов тиреоидных рецепторов
EA200100841A1 (ru) Оксаминовые кислоты и их производные в качестве лигандов тиреоидных рецепторов
ATE297905T1 (de) 6-azauracilderivate als liganden der thyroidrezeptoren
BR0203877A (pt) ácidos indol carboxìlicos como ligandos do receptor da tireóide, bem como composições e aplicações farmacêuticas compreendendo os mesmos
PT94377A (pt) Processo de preparacao de acidos imidazolilalcenoicos e de composicoes farmaceuticas que os contem
BR0000968A (pt) ácidos oxâmicos contendo ciano e seus derivados como ligantes de receptores da tiróide
EA199800290A1 (ru) (метилсульфонил) фенил-2-(5н)-фураноны в качестве ингибиторов циклооксигеназы-2
EA200300528A1 (ru) 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6
HK1098460A1 (en) Fused hetrocyclic compounds and their use as metabotropic receptor antagonists for the treatment of gastrointestinal disorders
EA200500392A1 (ru) Производные пиримидина и их применение в качестве модуляторов св2
EA200501710A1 (ru) Замещённые карбоновые кислоты
MY139541A (en) Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
EP1398029A8 (en) NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives
DK0994854T3 (da) Fremgangsmåde til fremstilling af en substitueret perhydroisoindol
EA200301143A1 (ru) Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6
DE60015508T2 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
MD553G2 (ru) Новые производные пиразолопиримидина антагонисты рецепторов ангиотензина ШШЖ способы их изготовленияб фармацевтические составы их содержащие
WO2004098498A3 (en) Indole acetic acid derivatives and their use as pharmaceutical agents
BRPI0414416A (pt) derivados de azetidinas 1,3-di-substituìdas para aplicação como antagonistas de receptores ccr-3 no tratamento de doenças inflamatórias e alérgicas
DK1373218T3 (da) Imidazolylderivater til anvendelse som histamin H3-receptorligander
UY26639A1 (es) Ácidos malonámicos y derivados de los mismos como ligandos de receptor tiroideo
MXPA05008802A (es) Un procedimiento de andamio combinacional para los farmacoforos de ligandos para receptores de urotensina ii y somatostatina 5.
ECSP003372A (es) Acidos oxamicos y derivados como ligandos de receptores tiroideos